



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/717,653	11/21/2003	Thomas P. Jerussi	4821-529-999	9144
20582	7590	10/11/2007		
JONES DAY 222 East 41st Street New York, NY 10017-6702			EXAMINER RAE, CHARLESWORTH E	
			ART UNIT	PAPER NUMBER
			1614	
			NOTIFICATION DATE	DELIVERY MODE
			10/11/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jpocket@jonesday.com
japarker@jonesday.com
wtokmakidis@jonesday.com

Office Action Summary	Application No. 10/717,653	Applicant(s) JERUSSI, THOMAS P.	
	Examiner Charleswort Rae	Art Unit 1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 June 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 41-52 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 41-52 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicant's arguments, filed 6/26/07, have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of actions being applied to the instant application.

This action is made final.

Status of the Claims

Claims 41-52 are currently pending in this application.

Response to applicant's arguments/remarks

Rejection under 103 (claims 41-52)

Applicant proffers that the rejection should be withdrawn for the following reasons:

1) None of the references cited by the examiner discloses or suggests anything whatsoever regarding enantionerically pure (S)-didesmethylsibutramine: Scott et al. teach racemic didesmethylsibutramine while Yound et al. teach (-) sibutramine).

2) Scott's disclosure that racemic didesmethylsibutramine may have pharmacological properties similar to racemic sibutramine cannot provide a basis to conclude that (S)-didesmethylsibutramine may be equated with (-) sibutramine in the same way.

3) Assuming, *arguendo*, that the references somehow suggest (S)-didesmethylsibutramine, the claims are still not obvious over the combination of

references cited by the Examiner because Scott and Young are silent regarding the treatment of narcolepsy.

4) Although Harrison's teach that antidepressants may be employed to relieve the symptoms of narcolepsy, this blanket statement does not provide any basis to conclude that any and all antidepressants are effective in treating such symptoms. This is further evidenced by the fact that Harrison's also teach that compounds including viloxzine hydrochloride and fluoxetine are under evaluation for narcolepsy (Harrison, page 167, last paragraph). This clearly implies that each and every antidepressant must be separately evaluated for their efficacy and/or safety for the treatment of narcolepsy.

5) The combination of Harrison, Scott, and Young would not have provided any meaningful guidance to a skilled practitioner at the time of conception of the presently claimed invention.

6) Based on the general prior art, a skilled artisan would not have been led to investigate didesmethylsibutramine, much less enantiomerically pure (S)-didesmethylsibutramine in view of Luscombe et al. (Neuropharmacology. 1989;28(2):139-134; provided as an attachment hereto as Exhibit A). Luscombe et al. teach that "the secondary and primary amine metabolites" of sibutramine exhibit similar in vivo pharmacological activity to the parent compound (abstract and Table 1 on page 131). Thus, despite Scott's purported disclosure that didesmethylsibutramine may be 100 times more potent than sibutramine in vitro, those of ordinary skill in the art reading Luscombe's disclosure would not have been led to use didesmethylsibutramine on the

Art Unit: 1614

face of the disclosure that no difference in pharmacological activity in vivo is observed for didesmethylsibutramine

-pharmacological profile but for other reasons, including pharmaceutical reasons

7) With respect to the rejection based on Scott/Young/Harrison, further in view of Gundlah (Pharmacology and Experimental Therapeutics. 1997;283(2):581-591), the combine cited references still do not disclose or suggest enantiomerically pure (S)-didesmethylsibutramine or the treatment of narcolepsy using (S)-didesmethylsibutramine.

In response, the rejection is maintained as applicant's arguments are not found to be persuasive for the following reasons:

a) The cited references establish a prima facie case of obviousness for the reasons set forth below in connection with the 103(a), which are incorporated by reference.

b) Applicant's conclusory statement that there is no specific suggestion or teaching in the references to combine prior art is not found to be persuasive as KSR forecloses the argument that a **specific** teaching, suggestion, or motivation is required to support a finding of obviousness (See the recent Board decision Ex parte Smith, -- USPQ2d--, slip op. at 20, (Bd. Pat. App. & Interf. June 25, 1007, citing KSR, 82 USPQ2d at 1396)

c) Contrary to applicant's interpretation of Luscombe et al., Luscombe's teaching that "the secondary and primary amine metabolites" of sibutramine exhibit similar in vivo pharmacological activity to the parent compound (abstract and Table 1 on page 131) would reasonably have provided motivation to an artisan skilled in the art to investigate

Art Unit: 1614

the therapeutic effects of enantiomerically pure (S)-didesmethylsibutramine (i.e. for treatment of narcolepsy), at least to evaluate its side-effect profile, with reasonable predictability in view of the combined teaching of the cited references.

d) Applicant's assertion that the cited references do not teach enantiomerically pure (S)-didesmethylsibutramine ignores the fact that independent claim 1 encompasses varying degrees of enantiomeric purity as evidenced by dependent claims 42-45. Besides, in the absence of a clear specific definition of the term "enantiomerically pure (S)-didesmethylsibutramine," this term given its broadest reasonable possible interpretation is construed to encompass racemic mixtures of (S)-didesmethylsibutramine wherein pure (S)-didesmethylsibutramine is present in an amount above 50 percent by weight of the didesmethylsibutramine in view of the instant disclosure (see specification, page 5, lines 12-28).

Claim rejections – 35 USC 103(a)

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 41 and 48-52 are rejected under 103(a) as being unpatentable over Scott et al. (Scott et al. The effects of BTS 54 505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the dorsolateral geniculate nucleus in vivo. Br. J. Pharmacol., 111:97-102 (1994), in view of Young (WO 94/00114), and in view of Harrison's Principles of Internal Medicine (1994).

The above discussion of the 103(a) rejection in connection with the Response to applicant's arguments/remarks is incorporated by reference.

Scott et al. The effects of BTS 54 505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the dorsolateral geniculate nucleus in vivo. Br. J. Pharmacol., 111:97-102 (1994). Scott et al. teach that the primary and secondary amine **metabolites of sibutramine** (i.e. BTS 54 505, or desmethylsibutramine, and BTS 54 3554, or **didesmethylsibutramine**) have a similar pharmacological profile to the parent compound in vivo, but are up to 100 fold more potent than sibutramine as monoamine uptake inhibitors in vitro (page 97, column 1, lines 11-16; see also Figure 1). Claim 41 recites the term "enantiomerically pure (S)-didesmethylsibutramine." Scott et al. also teach the *in vitro* data indicate that the pharmacological effects of sibutramine *in vivo* are mainly due to the activity of its primary and secondary amine metabolites (page 97, column 1, lines 16-20). Scott et al. also disclose that tricyclic antidepressants have a number of side effects which arise

Art Unit: 1614

from their affinity for muscarinic cholinceptors and histamine receptors; these side effects may limit their therapeutic use in the treatment and/or prevention of NMDA-induced toxicity and neurodegeneration (page 101, column 2, last paragraph, lines 15-21). Scott et al. further disclose that since sibutramine and its active metabolite BTS 54 505 have no significant affinity for muscarinic receptors, $\alpha 1$, $\alpha 2$, β adrenoceptors, dopamine D1 and D2 receptors, and 5-HT1 and 5-HT receptors, sibutramine and BTS 54 505 may result in fewer and less pronounced side-effects than the tricyclic antidepressants (page 101, column 2, last paragraph, lines 21-27). Scott et al. do not teach the instant method for treating narcolepsy comprising a therapeutically effective amount of "*enantiomerically pure (S)-didesmethylsibutramine*."

Young, JW (WO 94/00114) teach compositions containing **optically pure (-) sibutramine**, which possess potent activity in treating depression, obesity and weight gain, and useful in treating disorders ameliorated by inhibition of neuronal monoamine reuptake inhibitor; sibutramine inhibit the reuptake of several monoamines such as dopamine, noradrenaline, and serotonin (page 1). Young, JW teach disorders ameliorated by neuronal monoamine reuptake inhibition to include, but are not limited to, Parkinson's disease and depression (page 2, lines 2-4). In addition, Young teaches that the magnitude of a therapeutic dose of (-) sibutramine in the acute or chronic management of a disease will vary with the severity of the condition to be treated and the route of administration (page 18, line 33 to page 19, line 5). Young teach that the recommended daily dose of (-) sibutramine range from about 1 mg to about 60 mg per day (page 19, lines 5 to 9). Young also teaches that any suitable route of administration

Art Unit: 1614

may be employed for providing the patient with an effective dosage of (-) sibutramine e.g. oral, rectal, parenteral, transdermal; dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like (page 21, lines 7-14). In addition, Young teaches that the magnitude of a therapeutic dose of (-) sibutramine in the acute or chronic management of a disease will vary with the severity of the condition to be treated and the route of administration (page 18, line 33 to page 19, line 5). Young teach that the recommended daily dose of (-) sibutramine range from about 1 mg to about 60 mg per day (page 19, lines 5 to 9). Young also teaches that any suitable route of administration may be employed for providing the patient with an effective dosage of (-) sibutramine e.g. oral, rectal, parenteral, transdermal; dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like (page 21, lines 7-14). Based on the teaching of Young et al., an artisan skilled in the art at the time the instant invention was made would reasonably have predicted that enantiomerically pure (S) **didesmethylsibutramine** would exhibit the same pharmacologic profile as the parent racemic didesmethylsibutramine in view of the fact that enantiomerically pure (-) sibutramine also exhibited the same pharmacologic profile as racemic sibutramine. Young does not teach narcolepsy.

Harrison's Principles of Internal Medicine (1994) teaches that the diagnosis of narcolepsy require the presence of the "narcolepsy tetrad," consisting of 1) excessive daytime somnolence, 2) cataplexy, 3) hypnagogic hallucinations (the occurrence of vivid hallucinationary dream imagery at sleep onset), and 4) sleep paralysis (an awareness that voluntary musculature is paralyzed coincident with the onset of sleep (page 167, 4th

Art Unit: 1614

full paragraph). Instant claim 41 recites the term "[a] method of treating narcolepsy." Harrison's teaches that even though early experimental studies that focused on the raphe nuclei of the brainstem appeared to implicate serotonin as the primary sleep-promoting neurotransmitter, subsequent work has demonstrated that the raphe-serotonin system may facilitate sleep but is not necessary to its expression; the extensive pharmacology of sleep and wakefulness suggests roles for other neurotransmitters as well (page 165, column 1, 3rd full paragraph). Harrison's also teaches that treatment of **narcolepsy** is symptomatic (page 167, second to last paragraph, line 1). Harrison's teaches that treatment of cataplexy, hypogogic hallucinations, and sleep paralysis require antidepressants and that the efficacy of protriptyline, the most commonly used anti-cataplectic in the United States, is limited by its anticholinergic side effects (page 167, column 2, last two paragraphs).

Based on the teaching of Scott et al. that the primary and secondary amine metabolites of sibutramine (i.e. desmethylsibutramine and didesmethylsibutramine) have a similar pharmacological profile to the parent compound in vivo, but are up to 100 fold more potent than sibutramine as monoamine uptake inhibitors in vitro, coupled with the teaching that sibutramine and BTS 54 505 may result in fewer and less pronounced side-effects than the tricyclic antidepressants, someone of skill in the art at the time the instant invention was made would have been motivated to combine the teaching of Scott et al., in view of Young, and in view of Harrison's to create a method of treating narcolepsy comprising administering to a patient BTS 54 505 or BTS 54 354. To the extent that the racemate of BTS 54 505 and BTS 54 354 comprises the instant claimed

individual isomers, the instant claimed isomers are reasonably considered to be obvious variants over the corresponding racemate because of their presence in the racemate. It would further be expected that one of the instant isomers would be more active than the other and the racemate exhibit the combined effects.

Pharmaceutically acceptable salts, or solvate, or hydrate of BTS 54 505 and BTS 54 354, the routes of administration of the instant claimed isomers are reasonably considered to be within the capabilities of the artisan of ordinary skill in the art in the absence of evidence to the contrary. Claim 48 recites the term "*wherein the (S)-didesmethisibutramine is administered orally, mucosally, rectally, transdermally, topically or parenterally;*" claim 49 recites the term "administered orally;" claim 50 recites the term "administered parenterally;" claim 50 recites the term "administered intravenously, intramuscularly or subcutaneously;" claim 52 recites the term "wherein the solvate is a hydrate." Also, the term "therapeutically effective amount" is construed to be reasonably within the knowledge and scope of an artisan skilled in the art without the need to resort to undue experimentation. Claim 41 recites the term "therapeutically effective amount."

Thus, someone of skill in the art at the time the instant invention was made would have found it obvious to create the instant invention with a reasonable expectation of success in view of Scott et al., in view of Young, and in view of Harrison's.

Claims 42-47 are rejected under 103(a) as being unpatentable over Scott et al., in view of Young, in view of Harrison's, and further in view of Gundlah et al. (Gundlah et

Art Unit: 1614

al. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. Pharmacology and Experimental Therapeutics, 283 (2):581-591 (1997); **electronic copy**, pages 1-18).

The above discussions of Scott et al., Young, and Harrison's are incorporated by reference.

Gundlah et al. teach that BTS 54 505 produce a dose-dependent increase in hypothalamic 5-HT following systemic administration of 1, 3, and 10 mg/kg i.p. to rats (see Methods, pages 3-4). Although Young and Gundlah et al. do not specifically teach sibutramine metabolite administered in doses of 0.1 to 60 mg per day, or the specific relative ratios of the isomers, these limitations are within the skill of the ordinary artisan in the art and are considered to constitute pharmaceutical optimization in the absence of evidence to the contrary. For example, claim 45 recites the term "wherein the amount of (S)didesmethylsibutramine administered is from about 0.1 to about 60 mg per day;" claim 46 recites the term "wherein the amount of (S)didesmethylsibutramine administered is from about 2 mg to about 30 mg per day;" while claim 47 recites the term "wherein the amount of (S)didesmethylsibutramine administered is from about 5 mg to about 15 mg per day." The terms "wherein the (S)-didesmethylsibutramine comprises greater than about 80 percent by weight of didesmethylsibutramine as recited in claim 42;" "wherein the (S)-didesmethylsibutramine comprises greater than about 90 percent by weight of didesmethylsibutramine as recited in claim 43;" and the term "wherein the (S)-didesmethylsibutramine comprises greater than about 95 percent by weight of didesmethylsibutramine as recited in claim 44;" are reasonably construed

Art Unit: 1614

to be within the scope and knowledge of an artisan skilled in the art in the absence of evidence to the contrary.

Based on the teaching of Scott et al. that the primary and secondary amine metabolites of sibutramine (i.e. desmethylsiburamine and didesmethylsibutramine) have a similar pharmacological profile to the parent compound in vivo, but are up to 100 fold more potent than sibutramine as monoamine uptake inhibitors in vitro, coupled with the teaching that sibutramine and BTS 54 505 may result in fewer and less pronounced side-effects than the tricyclic antidepressants, someone of skill in the art at the time the instant invention was made would have been motivated to combine the teaching of Scott et al., in view of Young, in view of Harrison's, and further in view of Gundlah et al. to create a method of treating narcolepsy comprising administering to a patient BTS 54 505 or BTS 54 354.

Thus, someone of skill in the art at the time the instant invention was made would have found it obvious to create the instant invention with reasonable predictability.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 1614

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charlesworth Rae whose telephone number is 571-272-6029. The examiner can normally be reached between 9 a.m. to 5:30 p.m. Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached at 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 800-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

18 September 2007
CER

BRIAN-YONG S. KWON
PRIMARY EXAMINER

A handwritten signature in black ink, appearing to be 'B. Kwon', with a long horizontal line extending to the right.